You would have to assume US only given ACADA only has US rights and the analyst is likely only commenting on the peak sales that are relevant to ACADIA.
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference, page-68
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.01 |
Change
-0.715(3.45%) |
Mkt cap ! $2.570B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $2.702M | 134.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 343 | $20.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.01 | 254 | 6 |
View Market Depth
| Last trade - 13.13pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |